International Cat Care has launched a competition in which veterinary practice staff are invited to take a 'selfie' of themselves with their favourite cat and upload it to the International Society of Feline Medicine (ISFM) Facebook page (www.facebook.com/ISFMcats), where cat lovers from around the world can vote for their favourite.
The Cattitude competition is designed to raising awareness of the charity's global Cat Friendly Clinic initiative.
The photograph that gets the most Facebook 'likes' will be used by the charity to help raise awareness of the Cat Friendly Clinic programme, which aims to promote the wellbeing of cats visiting or being hospitalised in a veterinary practice. Accredited Cat Friendly Clinics fulfil a set of broad criteria that show they recognise the specific needs of cats and their owners, and place cat welfare high in their practice priorities. Cat owners in turn are able to seek out clinics that have taken steps to help them overcome common barriers to clinic visits and reduce the stress of their pet.
The Cattitude competition runs from now until the 24th April. The winning staff member will receive £200 worth of John Lewis vouchers and the practice £400 worth of Thames Medical vouchers to be spent on feline-friendly equipment.
Practices may upload as many photos as they like to the Facebook page, and will be able to encourage clients to 'Like' their photos with campaign support materials which include downloadable in-clinic display posters, a series of supplied posts for their own Facebook page, written copy for their own clinic newsletter or email along with a proforma press release they can send to their local newspapers and publications.
Clinics can find more information on taking part in the Cattitude competition at www.facebook.com/ISFMcats orwww.icatcare.org/cattitude. Details of the ICC Cat Friendly Clinic initiative and accreditation can be found atwww.catfriendlyclinic.org along with a list of already-accredited vet clinics.
Nockolds Solicitors was approved as the new administrator of the ADR trial by RCVS Council at its June 2016 meeting at Cardiff City Hall. The company was identified and approved by the RCVS Operational Board as meeting its requirements, a decision which the RCVS says has been welcomed by the Veterinary Defence Society and the British Veterinary Association, as well as receiving lay and consumer support.
The current trial, which was launched in November 2014 and is administered by Ombudsman Services, will come to a close by 1 October, when the new trial with Nockolds will start.
Nick Stace, RCVS Chief Executive and Secretary, said: "In order to be able to make an informed choice about how we wish to design and implement a permanent ADR scheme we wanted to ensure that we have as many different options and as much data as possible. It is very important that we get the permanent scheme right and this is why Operational Board made the decision to have a second trial. It was also clear that satisfaction levels from consumers for the previous trial were lower than we would have liked and that we therefore need to explore other options.
"It is important to note that this will not just be a re-run of the first trial with a different administrator – there will be some significant differences between this and our first trial with Ombudsman Services.
"First, this will be a truly alternative process as consumers will be able to access the trial directly rather than having to go through the College’s concerns process first.
"Second, this will be a process of mediation meaning that expert advisors from Nockolds will facilitate communication between the complainant and the veterinary surgeon to try and find a satisfactory solution to the concern."
The trial will be promoted to both the public and the profession as an alternative to the College’s formal concerns investigation process and participation in the trial will be voluntary. There will also still be a panel of veterinary advisors overseeing the trial and helping staff at Nockolds with any clinical queries they may have.
Jennie Jones is a Partner at Nockolds and will head up the trial. She said: "We are committed to providing a service that mediates complaints to find a fair, efficient and proportionate resolution. We are looking forward to working with everyone involved in veterinary profession to develop an effective mediation service that can be accessed by both the public and members of the profession.
"The service will focus on finding effective and practical resolutions. Understanding the root cause of the complaint and re-establishing effective communication are the crucial first steps in mediation and helping the parties to find a solution they can both accept. Over the coming months, we will be working with the RCVS, representative bodies for the profession and consumers to launch the service.
"In addition to mediating complaints, we will share insight in mediation and complaint resolution to inform practitioners and stakeholders and to enhance standards at veterinary practices. This enables complaint analysis to be used to help improve client care, avoid complaints and maintain trust and confidence in the profession."
A bespoke website for the trial will be set up in time for the launch on 1 October 2016.
New subject areas include emergency planning, traffic accidents, excessive bleeding, seizures, poisonings, choking and breathing problems, caesareans, GDV and abdominal emergencies, and pain assessment and management.
ECC is the first element of the new Practical and Clinical Skills section of the BSAVA’s online Professional Development Phase (PDP) Resource Bank, and takes the total to more than 100 hours of free online CPD support matched directly to the RCVS PDP competences.
The BSAVA PDP resource bank is designed to help veterinary surgeons to enhance practice expertise, develop their practices’ professional and business skills, and advance an ethos of reflective learning and continuous professional development (CPD) alongside veterinary expertise.
Members can pick and choose the most appropriate content for their professional development from more than 250 resources in multiple formats to suit a range of learning preferences, including short ‘how to’ videos, webinars written by and featuring veterinary specialists, podcasts, documents and interactive PDFs and web links.
BSAVA President John Chitty said: "BSAVA continues to lead the way in CPD learning resources and this easily accessible and flexible PDP Resource Bank has proven very popular in helping members to meet the challenges of delivering 21st century veterinary medicine."
The BSAVA PDP Resource Bank content is reviewed by committee and there will be ongoing development of new resources – including employer specific resources for practices supporting new graduates.
For more information visit www.bsava.com/pdp
The company says its Skinsights Learning Academies help support individuals and practices improve the healthcare outcomes for the 25% of dogs medicalised by skin problems in the UK.
A number of recognised industry professionals will be giving interactive, bite-sized talks at the events, including: Filippo De Bellis, Ian Wright, Jill Maddison, Sarah Warren, Rob Pope, Evelyn Maniski and Emily Robson as well as Zoetis veterinary and business consultants.
Zoetis says all the presentations will be highly practical, presented through case reviews, research, workshops and discussions. They will offer the latest information on game-changing therapeutics, best practice work-ups, effective protocols and insightful case-studies.
The sessions are limited to groups of 30 and Zoetis says places are expected to fill quickly.
To reserve your free place, visit: http://www.zoetis.co.uk/LVS2018
If you are unable to secure a seat in the theatre, headsets will be available on the day so you can listen to the lectures whilst on the stand.
Given that vapocoolant is effective immediately, compared to EMLA cream which is recommended to be applied 60 minutes beforehand, the study suggests that in dogs at least, vapocoolant may be the better option in practice.
For the study, researchers from the Royal Veterinary College assessed 83 dogs and 18 cats requiring intravenous catheterisation for either blood donation collection or as oncology patients.
Patients were randomly assigned to receive either EMLA cream or a swab saturated with vapocoolant spray (Ethycalm / Invicta Animal Health) applied before catheterisation, and their reactions were assessed during initial restraint, limb handling, swab application and skin puncture.
Overall, there was no significant difference between vapocoolant spray and EMLA cream, and neither method appeared better at improving patient tolerance of intravenous catheter placement.
Vapocoolant spray was less effective than EMLA cream in reducing adverse reactions to skin puncture during catheterisation in cats, suggesting that EMLA may be preferable for feline patients.
Dogs that received vapocoolant spray showed a greater adverse response during swab application compared to those receiving EMLA, possibly due to the coldness of the swab.
Success of intravenous catheter placement was identical for both anaesthetics.
Dr Richie Trinder, lead author of the study, said: “The study is the first of its kind comparing vapocoolant spray and EMLA, and suggests in this context that the use of vapocoolant spray provides a similar degree of relief as EMLA, but with the added advantage of being instantaneous, instead of needing to wait the recommended 60 minutes for EMLA.”
Reference
The association says the new Recognised Internships significantly enhance its existing programme which just listed available internships in equine practice.
Over the past year BEVA has worked with veterinary practices across the UK to develop a set of core skills that should be covered during an internship.
These standards sit alongside BEVA's existing Employment Toolkit which outlines what a new graduate should be considering when applying for a job (such as working hours, pay, CPD allowance).
Roger Smith, BEVA Junior Vice President said: “The new programme gives practices constructive guidance to provide a positive and inspirational introduction to a career as an equine vet, rather than the perhaps rushed and unintentionally unstructured, labour focused junior positions that have been experienced in times past.”
BEVA Chief Executive David Mountford said: “We are delighted that nearly 40 equine veterinary practices have already signed up to our Recognised Internships initiative.
"It is such a positive sign that as a profession we are all committed to ensuring we can offer the best start to those entering the profession.”
https://www.beva.org.uk/internships
Practices interested in joining the scheme should contact Fiona Cunnington - fiona@beva.org.uk
A new survey by Petplan has given an insight into how veterinary nurses regard their job.
The survey, conducted at BVNA Congress, found that 73% of nurses feel that clients do not have a sufficient understanding of their role in practice.
Louisa Baker, the 2008 Petplan Vet Nurse of the Year, said: "Clients are often not aware of the skills required to be a vet nurse. Most clients believe we just handle the animals whereas we are often involved with surgical activities such as stitching and preparing drips."
Arguably, if pet owners under-appreciate the role of the nurse in practice, then they might also be expected to place a lower financial value on the care they provide. If that is the case, then it makes a lot of sense for vets and practice owners to find novel ways of communicating the breadth of work that nurses do, and its importance, to clients.
Other findings included 40% of nurses agreeing that direct contact with animals, such as caring for them through recovery, is the best part of the job. 54% told Petplan that they find the job extremely rewarding.
Nearly all nurses (99%) said that they value training and CPD to further their careers.
To support this desire to learn, Petplan has launched its Petplan Insurance Advisor training scheme. Already, over 500 nurses have completed one of the scheme's CPD qualifying modules.
The scheme enables the development of individual skills such as the ability to sell products and gain confidence with clients. Available online, vet nurses can participate in the scheme at work or at home. Visit http://www.petplanpia.co.uk/ for more information.
The British Safety Council has launched a new qualification to help people who drive as part of their work stay safe on the roads.
According to the organisation, the Level 2 Award in Safe Driving at Work provides work drivers with key knowledge of the hazards and risks associated with driving and equips them with valuable guidance on the measures available for reducing these risks, such as vehicle inspection, behaviour and defensive driving.
According to estimates from the Health and Safety Executive (HSE), up to a third of all road traffic accidents in Britain involve someone involved in work-related activity. In 2013, according to government figures, 1,713 people died on the road, with the total number of casualties standing at 183,670.
The Ofqual-regulated qualification, which is designed to be delivered by employers or training organisations, instructs learners on a range of topics including the particular risks associated with vulnerable road users, such as cyclists and pedestrians, the importance of regular vehicle safety checks and how to adapt driving style in response to changes in driving conditions or the actions of others.
Alex Botha, the British Safety Council's Chief Executive, said: "Driving can be a risky activity, a fact borne out by the high number of injuries and fatalities that occur annually on our roads.
"However, simple steps can be taken by employers and drivers to manage and reduce this risk. Our new Level 2 Award in Safe Driving at Work provides learners with all the essential knowledge to help them stay safe on the roads.
"Learners can expect to leave the qualification with a thorough knowledge of the main risks posed by driving - whether to themselves or other road users - and how to reduce them.
"Once registered with us, employers or training centres deliver the training using the high-quality teaching and student materials provided. Qualifications are assessed through a 45-minute multiple-choice examination that can be either taken online or on paper.
"This is a stand-alone qualification designed for delivery as a short course. It is also well-suited for integration into wider vocational programmes of study or, for example, as part of an induction programme. Students need no former knowledge or experience, so can come from a diverse range of educational and employment backgrounds.
"Safer driving habits should also feed through into workers' personal lives, providing employers with a valuable corporate social responsibility tool to help make our roads safer in and out of work."
The poster gives information about things like lillies, chocolate, raisins, fertilisers, weedkillers and adders.
TVM will also be running its annual social media campaign about the most common spring dangers, giving practices digital content which they can share with clients.
To get a poster for your practice, contact your local TVM territory manager or visit https://www.tvm-uk.com/pet-dangers-order-free-display-materials-for-your-practice.
Vita Referrals has been set up by Rob Quinn, an RCVS and EBVS Specialist in Small Animal Surgery, and Nick Blackburn and Stuart Cooke, both RCVS Advanced Practitioners in Small Animal Surgery.
They say that their aim is to ensure every pet owner has access to reasonably priced surgical care.
To that end, the clinic lists fixed costs for all of its major surgical specialities on its website, where it says clients should notice a significant reduction compared to other providers.
It also offers a 12-month post-surgical complications warranty.
Rob said: “Many pet-owners are unaware that there are three major companies which own the vast majority of veterinary practices in the UK.
"That is not necessarily of benefit to those using the services, as prices can rise when competition is low.
"Myself, Nick and Stuart felt very strongly that there was a different way to do things.
“No one becomes a vet to see animals suffer or pet-owners struggle to make tough financial decisions.
"We knew it was possible to offer a top quality service, with the best facilities and equipment available, whilst also keeping prices at a realistic level – and that is where the vision for Vita Referrals came from.
"We also wanted the freedom to offer collaborative decision-making, the removal of complex forms and bureaucracy and what we believe is an industry-leading 12-month complications guarantee on routine surgeries.
"It’s time there was more disruption and competition in the sector – and that will, ultimately, only be a good thing for pets, owners and vets.”
www.vitareferrals.co.uk
Fort Dodge has announced that a challenge study has demonstrated the ability of Duvaxyn® IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Sydney/07 (H3N8) two weeks after a two dose primary course. This strain was responsible for the financially devastating equine influenza outbreak in Australia in August 2007.
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. According to Fort Dodge, experts at a recent WHO meeting on human vaccines expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine*.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Sydney/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Helen Barnes, EMEA Equine Business Manager for Fort Dodge, said: "The results of this challenge study provide reassurance for owners that horses vaccinated with Duvaxyn will be protected against circulating strains of equine influenza, including the Sydney strain which proved so damaging.
"As the benefits offered by whole virus technology are increasingly recognised, the popularity of vaccines based on this technology is re-emerging, particularly to combat a potential pandemic.
"The entire Duvaxyn range of equine vaccines, including the recently licensed Duvaxyn WNV for West Nile Virus, are based on the whole virus approach as we believe it offers a broad and consistent level of protection."
SRUC, which is the biggest provider of veterinary nursing, livestock husbandry and animal care training in Scotland, says it will offer a core veterinary programme to address existing shortages in veterinary provision, in areas such as rural veterinary practice, food production, food safety and animal and public health.
The College is first establishing a working group to progress the plans for the school. The group will be chaired by Professor Sir Pete Downes, former Principal and Vice-Chancellor of the University of Dundee.
Sir Pete will be joined by Sheila Voas, Chief Veterinary Officer for Scotland, former NFUS President Nigel Miller, SRUC Board member Jane Craigie, and Dr Kate Richards, who is a non-executive director on the SAC Commercial Board and currently the junior vice president of the RCVS, in line to become President in July.
Professor Caroline Argo, currently Dean of SRUC’s North Faculty, will lead the project for SRUC.
A report from BiGGAR Economics has found that the vet school could add £26 million GVA and 242 jobs to Scotland by 2030.
Professor Wayne Powell, Principal and Chief Executive of SRUC, said: “We are an ambitious institution with a bold vision for the future. This is a ground-breaking model to expand access to educational opportunities and broaden the range of potential students who would not ordinarily be able to attend a vet school. It will also help solve existing skills shortages across Scotland.
“We see a key role of the new vet school in sustaining primary agriculture and hence food and drink productivity, with the welfare of both livestock and companion animals at its heart. The school will produce champions for best-in-class animal welfare in support of these industries, which will help improve productivity, effectiveness, and sustainability.”
“Building on the excellent new facilities we have already announced for Aberdeen and Inverness, there is a lot of work still to be done, but we are ready to seize the opportunity.”
Ceva Animal Health has added a new CPD module to its Cardio Academy website which focuses on common heart diseases in cats.
The 20 minute online seminar is hosted by Virginia Luis-Fuentes, Professor of Veterinary Cardiology at the Royal Veterinary College. After viewing the module, you can claim a CPD certificate by answering questions relating to the session.
Fraser Broadfoot MRCVS, product manager at Ceva, said: "Cardio Academy is going from strength to strength with over 1500 UK vets registered to the site which now includes 15 hours of free on-demand cardiology CPD with leading specialists."
For more information, visit: www.cardioacademy.cevalearn.com.
The university says it has implemented a range of health and safety measures to meet Government guidelines and allow for the controlled return of 150 first-year undergraduate students to its Sutton Bonington campus.
Since the latest cohort joined the university at the height of the UK lockdown, the school has delivered a programme of technology-assisted Fresher’s Week and teaching activities.
However, the return of the April cohort will enable face-to-face teaching that cannot be delivered remotely, specifically essential animal handling and health and safety skills required before students can embark on the work experience element of their course.
The practical sessions will form part of a blended approach to learning, with other lectures and tutorial support continuing to be delivered remotely to reduce the number of students in teaching buildings at any one time.
Dean of the School of Veterinary Medicine and Science Professor Gary England said: “We have missed being on campus with our students tremendously during the coronavirus lockdown and we are excited to be welcoming this cohort to Sutton Bonington in July.
“The health and safety of our students and staff has remained our top priority and has been at the heart of our planning process. Colleagues from across the university have been working intensively on the intricate detail required to ensure that adequate social distancing and hygiene measures are in place to allow this first step in a return to campus.”
Among the measures which have been introduced are:
The university says the return of its vet school cohort and the re-starting of face-to face-education at University of Nottingham Ningbo China at the end of April, where 5,000 students are now back on campus, will form the blueprint for the return of the majority of students to its UK campuses when the new academic term begins on 21 September.
Ceva Animal Health has launched Marboxidin chewable tablets for dogs and cats for the treatment of micro-organisms susceptible to marbofloxacin, including skin and soft tissue infections (in cats and dogs), respiratory tract infections (in dogs and cats) and urinary tract infections (in dogs).
Containing marbofloxacin as its active ingredient, Marboxidin has a taste-masking lipid coating to ensure that its bitterness is not detected. In palatability trials over 90% of dogs and 80% of cats voluntarily consumed Marboxidin chewable tablets from the hand or in food1. Ceva says that Marboxidin is also very cost-effective, with an ongoing discount using the new CevaSave rebate scheme.
Marboxidin chewable tablets are available in three tablet sizes (5mg, 20mg and 80mg).
For further details, contact your Ceva Territory Manager or telephone the customer support team on (01494) 781510.
References
Newmarket-based Test and Treat was one of three finalists, for its U-Treat test which enables vets to diagnose a UTI and get antibiotic sensitivity results in an hour.
Rachel Kirkby MRCVS, Business Development Director at Test and Treat, said: "It’s a great accolade to be recognised by such a prestigious award. The Vet Record Innovation Award celebrates new innovations that can bring about improvement and make a real difference to vets in practice – and that’s exactly what we’re aiming to do with U-Treat.”
The second finalist was the Animal Welfare Assessment Grid, developed by Public Health England (PHE), in collaboration with the University of Surrey School of Veterinary Medicine. Initially developed in zoos, rescue and research centres, there are plans now to develop it for use in small animal practice and in the farm sector.
The overall winner was PBD Biotech for Actiphage, its test for bTB and Johne's disease which gives very early detection, thereby allowing vets and farmers to prevent the spread of infection.
For more information, visit: https://bvajournals.onlinelibrary.wiley.com/doi/10.1002/vetr.267
The study, titled The Veterinary Employment, Engagement and Retention Study (VEER), opened this week and aims to collect data from thousands of veterinary professionals across the United Kingdom and beyond.
Dr Dermot McInerney (pictured right), VetX Head of Research and Partnerships, said: “We will use the data collected to understand the factors influencing career happiness and how they impact on talent attraction and retention.
"We want to share this information with as many people as possible so we can work together to create a better, more sustainable situation for both employers and employees in veterinary practice.”
The study findings will be published later in 2022 and made available to all industry stakeholders.
All participants will receive a special report of the results with customised career advice, and be entered into a weekly draw to win a prize.
To take part in the survey, visit: www.vetxinternational.com/veer.
Preliminary results, which recorded a decline in the quantities of antimicrobials prescribed from 2014 to 2018, were published in 2022.
A further audit has now been undertaken in all 22 of the company's first opinion practices to investigate the age, breed and estimated weight of each horse, the clinical indication for antibiotic use, the drugs prescribed, their dose rates, the route of administration and whether culture and sensitivity were used to guide antimicrobial selection.
Data collection was completed in August 2022.
This secondary audit was conducted using a ‘point prevalence’ survey, in which each CVS Equine first opinion Quality Improvement Lead gathered information about all systemic antibiotics prescribed by each of their practices on one day a month for 12 consecutive months.
The project yielded information on 331 cases where systemic antimicrobials were prescribed.
Complete data about the first line-drug selection were available for 261 prescriptions.
The commonest prescribed antimicrobial was sulfadiazine/trimethoprim (41%), followed by oxytetracycline (23%), procaine penicillin (16%), doxycycline (13%), gentamicin (4%), metronidazole (1%), ceftiofur (1%) and enrofloxacin (1%).
Highest priority critically important antimicrobials (ceftiofur and enrofloxacin) were only prescribed in four horses (clinical indications for these included possible sepsis, skin infection, lower respiratory tract infection and a wound complication – in none of these cases was the first-line drug selection based on the results of culture and sensitivity.
Overall, the clinical indications for antimicrobial use were recorded in 246 cases; the commonest indications were cellulitis/lymphangitis (27%), uncomplicated wounds (19%), surgical prophylaxis (15%), respiratory infections (11%) and skin infections (8%).
Hattie Lawrence, Director of CVS Equine, said: “Though the impact of this work is yet to be documented, there is anecdotal evidence that it has raised awareness amongst our veterinarians of the importance of antimicrobial stewardship.
"Taken together, the results of both pieces of work will be used to help develop and inform clinical audits and clinical guidelines of antimicrobial use in horses.”
Tom graduated from the Royal Veterinary College (RVC) in 2017 and joined Synergy Farm Health full-time in 2018, after completing his postgraduate diploma (PGDipVCP) with the RVC.
Nominated by his practice, Tom is described as a fine example of a dedicated caring professional who is passionate about sustainability, has a keen sense of his clients’ needs, and has developed strong working relationships with the farms under his care.
The judging panel found that Tom uses data effectively in herd health planning to highlight areas of improvement, working in partnership with his clients to promote disease prevention and profitability.
Tom’s clients spoke of his knowledge and caring attitude and how much he is valued as part of their team.
Tom said: “It was a privilege to be a part of the awards and to see farmers and businesses acknowledged - farmers don’t always get the recognition they deserve and seeing British dairying showcased was amazing.
"I hope winning is reward for the time and effort colleagues at Synergy put into young vets too, and that I can put it to good use supporting clients and working with other organisations within the dairy industry.
"My aim as a vet has been simply to support clients the best I could, both clinically and emotionally, so to have won made it a fantastic night and one I won’t be forgetting!”
The runner up as Charlie Mays of LLM Vets, who the judging panel praised for making effective changes on farm towards preventive healthcare and using data to assist with health and profitability.
Charlie also lobbies government to support the interests of the farmer and the industry.
Sabrina Jordan from Virbac said: ‘Virbac has been supporting dairy vets with products and services for over 50 years and recognise the commitment of young dairy vets to the profession.
"The standard of nominations into this category was outstanding, and our winner and highly commended nominees are a true credit to the veterinary profession, both are shining lights of the future’.
Merial has highlighted two new studies which the company says demonstrates the efficacy and safety of its canine NSAID, Previcox.
In the first study, Lecoindre and Pepin evaluated the beneficial effects of once daily administration of 5mg/kg Previcox to dogs suffering from osteoarthritis (OA) for 90 days. According to the company, response to treatment was excellent, with significant improvements observed in lameness scores, pain on manipulation of the affected joint and range of motion. Of particular note was the fact that the degree of improvement increased with duration of treatment, clearly demonstrating the benefits of longer term treatment. These results support the findings of a recent review of the safety and efficacy of long-term NSAID use in dogs with OA. The product's safety profile was also evaluated by means of biochemistry and haematology assessments. In addition, regular gastroscopic examinations were used to directly visualise the effect of treatment on the gastric mucosa. These safety assessments demonstrated that Previcox therapy was well tolerated, with no significant treatment related changes seen on biochemistry or gastroscopy, despite the fact that this was a geriatric population which included a number of dogs with a prior history of gastrointestinal tract disease.
Merials says the findings from a different study by Joubert, published in the South African Veterinary Journal, provide further confirmation of the beneficial effects of 90 days Previcox treatment in a geriatric population of dogs.
Commenting on the results of the two studies, Kevin Whelan, Merial's Veterinary Technical Manager said: "The outcome from these studies provide further evidence for the benefits of long term use of Previcox in dogs suffering from osteoarthritis. There is relatively little published information available on the use of NSAIDs in older dogs, and these results confirm that Previcox is well tolerated in this group of patients."
For further information about Previcox, please contact your local Territory Manager or call 0870 6000 123.
References:
Colin graduated from the RVC in 1992 and has worked as a clinical veterinary surgeon in a variety of first opinion practices and referral centres. He trained as a veterinary anaesthetist at Bristol and Cambridge Universities before moving into the pharmaceutical industry, gaining experience in drug development and technical support, and pre- and post-marketing, at a number of companies.
Colin said: “Animalcare is introducing a number of new and innovative medicines, such as Daxocox, its weekly NSAID to reduce breakthrough pain in dogs with osteoarthritis, to the veterinary sector. This makes it an exciting environment in which to provide technical support.
“I’m looking forward to exploring how my experience can be most useful in supporting Animalcare’s expansion and, more importantly, ensuring that the company’s customers receive the guidance and advice they need to optimise the effectiveness of Animalcare’s product range in treating their patients.”
For technical support, email: technical@animalcare.co.uk
The veterinary group is stumping up more than £100,000 for the initiative, which will enable 20 vets and nurses, and 56 new grads from across the group to work with the Worldwide Veterinary Service (WVS) and other overseas animal charities.
The grants are for £1,500 and those taking part will also get up to one week of paid time off work whilst they volunteer.
VetPartners CEO Jo Malone said: “We wanted to support colleagues to have a fantastic experience while improving their skills in a different environment.
"It will give people a chance to use their clinical skills to give back to charities which are doing great work.
“If you’re working in a veterinary practice in Europe, you have support from team members around you and great facilities and equipment compared to the more challenging conditions working for a charity overseas.
"Working in these more challenging environments while they are volunteering will help build resilience, as our team members are unlikely to have experienced anything like this before.
“Charities like the World Veterinary Service are working ethically to help animals that may or may not have ever had veterinary care, and are doing a great job so we are delighted to support them.”
Zoetis has announced that the European Commission has granted marketing authorization for Simparica™ (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age.
Dr. Balázs Capári, a Hungarian veterinary specialist in small animal medicine who participated in clinical trials of Simparica said: "The approval of Simparica gives veterinarians a new oral choice in parasite control for dogs. In my experience, Simparica has been shown to rapidly kill fleas and ticks with efficacy that persists for five weeks. Dog owners participating in the trials also reported that Simparica is very palatable; the chewable tablet was easily taken by their dogs. The convenience of a once monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection."
Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, said: "At Zoetis, we focus our innovation on the most pressing needs of veterinarians, and that is what guided us to develop a new oral choice to provide dogs with persistent protection from fleas and ticks and treatment of mites that cause sarcoptic mange. Simparica is a result of the collaboration of Zoetis scientists worldwide, who share a determination to develop new medicines that deliver real value to our veterinary customers and the animals in their care. We are excited to bring this innovative medicine, Simparica, to veterinarians and dog owners across Europe."
The active substance of Simparica is sarolaner, a new ectoparasiticide in the isoxazoline class, developed by Zoetis.
Zoetis says the marketing authorization for Simparica was based on the results of field studies conducted in seven countries, involving more than 800 dogs of various breeds from at least eight weeks of age and 1.3 kg of weight. Simparica was shown to provide efficacy for at least five weeks against ticks and fleas. It demonstrated a rapid onset of action, killing fleas before they have a chance to lay eggs and can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis. It proved effective in treating sarcoptic mange, a highly contagious skin disease in dogs.
In studies, Simparica killed all four species of tick dominant in Europe (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus) and species of flea that most frequently infect dogs in European countries (Ctenocephalides felis and Ctenocephalides canis). Simparica was well tolerated with no adverse events reported at the therapeutic dose.
Zoetis expects to launch Simparica in the EU in the first quarter of 2016. Simparica chewable tablets will be available in 5mg, 10mg, 20mg, 40mg and 80mg dosage strengths.
For more information about Simparica and full prescribing information, visit http://www.zoetis.com/products-services/companion-animals/dogs.
Vetoquinol has made changes to Zentonil®, its liver support range for dogs and cats.
New Zentonil® is the UK's FIRST palatable and divisible tablet range of S-adenosyl-methionine (SAMe) supplementation and now comes with the added benefit of choice: Zentonil® Advanced which contains pure SAMe plus silybin and Zentonil® Plus which contains pure SAMe only.
A patent pending microencapsulation technique protects the SAMe from the harmful effects of stomach acid, even when the tablet is split or chewed.
The ability to split the tablets makes administration more accurate and also makes the product more cost-effective for clients.
Vetoquinol's new Zentonil® formulations have proven SAMe bioavailability curves in a market where this particular type of data is often lacking
Simon Boulton, product manager said: "Our customers told us that they had difficulties associated with SAMe supplementation. We have listened to their comments and provided the solutions."
The new formulations will become available as wholesalers' Zentonil® stocks are depleted. If you wish to try new Zentonil® now, you can place an order for Zentonil® Advanced or Zentonil® Plus with your wholesaler.
For more information, please contact your local Vetoquinol sales representative or telephone the free practice support number - 0800 1698197.
The Smart Home Monitoring Kit for pets includes an indoor camera which comes with an in-built temperature sensor and night vision, a door sensor and a Smart Plug which can be remotely activated to turn on a radio, lamp, portable heater or fan to help keep animals content.
Although designed primarily for pet owners, Petplan says the kit is also being used by some veterinary practices to help provide additional security and monitoring capabilities within the practice.
The kit also contains an SD card allowing clients to share footage of their pet in the home with their veterinary surgeon when explaining behavioural symptoms. Likewise the practice will be able to record and share footage with their staff or clients.
Isabella Von Mesterhazy, Head of Marketing at Petplan, said: "For Petplan, keeping pets healthy always has been and always will be our priority. Spending time away from your pet can be hard, so the new pet Monitoring Kit addresses this problem by providing welcome peace of mind that they are safe and well. We are delighted to be able to offer Petplan veterinary practices and their staff the chance to get their hands on a Monitoring Kit at an exclusive price."
To find out more about the exclusive offer available for Petplan veterinary practices and staff until 9th December, visit petplanvet.co.uk.